By Michael Brown, CP Op-Ed Contributor | Thursday, October 15, 2020 Have you heard the latest?
By Michael Brown, CP Op-Ed Contributor | Thursday, October 15, 2020 Have you heard the latest?
The biotech industry has been soaring this year, with the SPDR S&P Biotech ETF (XBI) up 26.6% year to date so far. The race for a COVID vaccine has primarily driven this performance, but what if there was another segment of the biotech industry that top hedge fund managers are all going after right now?
Recovery from experimental heart attacks can be improved with an injection of a mixture of heart muscle cells, endothelial cells and smooth muscle cells, but results are limited by poor engraftment and retention, plus there are concerns about potential tumorigenesis and heart arrhythmia. Recent animal research in pigs has shown that using the exosomes naturally produced from a mixture of heart muscle cells, endothelial cells, and smooth muscle cells derived from human induced pluripotent stem cells yielded regenerative benefits that were the equivalent to the injected hiPSC-CCs. Exosomes are membrane-bound extracellular vesicles that contain biologically active proteins, RNAs and microRNAs that are well known to participate in cell to cell communication, and are actively studied as potential clinical therapies for a wide range of conditions.
Social media is buzzing with the claim President Trump, who is pro-life, used an antibody cocktail developed using human embryonic stem cells. Editor's note Oct 8:Thursday News 8 received further clarification from Regeneron spokesperson, Alexander Bowie.
DetailsCategory: DNA RNA and CellsPublished on Thursday, 08 October 2020 15:15Hits: 512 NEW YORK, NY, USA and PARIS, France I October 08, 2020 I Cytovia Therapeutics ("Cytovia"), an emerging biopharmaceutical company, announces today that it has entered a research and licensing agreement with Inserm to develop NK engager bi-specific antibodies and iPSC CAR NK cell therapy targeting CD38, a key marker of multiple myeloma. The licensing agreement has been negotiated and signed by Inserm Transfert, the private subsidiary of Inserm, on behalf of Inserm (the French National Institute of Health and Medical Research) and its academic partners.
Congratulations to Jeremy Simonetto (Year 8, St Patricks College) for being runner up in the 2020 UNSW Bragg Student Prize for Science Writing. Year 8 student at St Patricks College, Jeremy Simonetto, discusses the potential planet-changing uses for iPS cells in medical research in his entry, awarded runner-up in the UNSW Bragg Student Prize for Science Writing, under the 2020 theme The Big Ideas Saving the Planet
Japanese stem cell researcher Shinya Yamanaka ( , Yamanaka Shin'ya, born September 4, 1962) is a Japanese stem cell researcher, winner of the Nobel Prize.[2][3][4] He serves as the director of Center for iPS Cell (induced Pluripotent Stem Cell) Research and Application and a professor at the Institute for Frontier Medical Sciences at Kyoto University; as a senior investigator at the UCSF-affiliated J.
Patient Genotyping: Potential Key to Treating Alzheimer's ubmd.com
Key Developments in the Market: In March 2018, Kaneka Corporation announced that they have acquired a patent in the Japan for the creation of the method to mass-culture pluripotent stem cells including iPS cells and ES cells. This will help the company to use the technology to produce high quality pluripotent stem cells which can be used in the drug and cell therapy. In March 2015, Fujifilm announced that they have acquired Cellular Dynamics International.
Induced Pluripotent Stem Cells Market has been growing exponentially over time and has shown great potential in the near future. The growth of Induced Pluripotent Stem Cells Market is expected to see an amazing uproar as the market becomes increasingly popular
Recent Comments